Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
2019 · Journal of Clinical Medicine · 71 citations
https://doi.org/10.3390/jcm9010102
T
Tadaaki Yamada
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
562
Papers
6.2K
Citations
41
h-index
126
i10-index
Tadaaki Yamada is an academic researcher from Kyoto Prefectural University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 41, co-authored 478 publications.
ORCID: 0000-0002-6945-281XPapers by this author
worksClinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
2021 · Lung Cancer · 55 citations
https://doi.org/10.1016/j.lungcan.2021.08.015
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers
2021 · Communications Biology · 49 citations
https://doi.org/10.1038/s42003-021-02323-7
Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
2014 · Journal of Thoracic Oncology · 46 citations
https://doi.org/10.1097/jto.0000000000000170
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
2021 · Frontiers in Oncology · 38 citations
https://doi.org/10.3389/fonc.2021.630136
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
2024 · Cancer Letters · 18 citations
https://doi.org/10.1016/j.canlet.2024.217124
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat